A panel of medical experts discuss various categories of heart failure and their clinical implications.
This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD, CCNS, CCRN, CHFN, NE-BC, FAHA, FCCM, FHFSA, FAAN; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD. Axsom provides an overview of the current heart failure classification system, which categorizes patients based on ejection fraction (EF) and symptoms. Heart failure with preserved ejection fraction (HFpEF) has EF over 50% with elevated natriuretic peptides or signs of elevated filling pressures. Heart failure with reduced ejection fraction (HFrEF) has EF under 40%. There is also a midrange between 40% and 49% EF. Patients can move between categories over time. Even asymptomatic patients with only mildly reduced EF could be considered early-stage heart failure, where treatments could prevent progression. Albert emphasizes that once a patient has heart failure symptoms, they have the diagnosis even if symptoms later resolve. Heart failure is a chronic condition requiring lifelong treatment, as stopping treatment often leads to recurrence of worse symptoms within 2 years. Patients may feel their symptoms are stable, but it is important that they understand they have persistent heart failure that requires ongoing care. The updated classification system allows clearer categorization and more tailored management based on EF and symptom status.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
New PsA Data Highlight Long-Term Benefits of Bimekizumab
November 19th 2024A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).
Read More